CGTN
8.2.2021 17:39:08 CET | Business Wire | Press release
Chinese President Xi Jinping has sent New Year's greetings to Chinese people of all ethnic groups, wishing happiness and good fortune for the people and prosperity for the nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005631/en/
President Xi, also general secretary of the Communist Party of China Central Committee, extended the greetings during an inspection trip in southwest China's Guizhou Province prior to the Chinese New Year, which falls on February 12 this year.
"I'd like to extend Spring Festival blessings to people of all ethnic groups across the country. I wish everyone good health, happiness for their families, successful careers, and an auspicious Year of the Ox. I also wish our great motherland, with its beautiful mountains and rivers, much prosperity," Xi said.
During his trip, President Xi visited places including the city of Bijie and the provincial capital Guiyang, as well as a village, a residential community and a supermarket, from Wednesday to Friday.
His agenda also included a meeting with project leaders and core scientists of the Five-hundred-meter Aperture Spherical Radio Telescope (FAST) project in Guizhou. The FAST, held to be the world's most sensitive radio telescope, started operation on January 11, 2020.
On Friday's meet with scientists, President Xi called for a greater focus on scientific innovation and making it a driving force for China's development.
President Xi also spoke highly of the achievements made over the past year in Guizhou Province, as he heard a work report by the Guizhou Provincial CPC Committee and the provincial government on Friday.
He pointed out innovative development is an inevitable prerequisite of fostering China's new development paradigms and urged efforts to accelerate the integration of big data and the real economy and foster strategic merging industries.
More should be done to stimulate consumption demand and develop new consumption models, so as to unleash the consumption potential to the full, Xi said.
He demanded an effective transition from consolidating poverty alleviation achievements to promoting rural vitalization.
President Xi also expressed his great confidence in the future of the region, and wished it could make new achievements in the construction of ecological civilization.
A path of high-quality development that prioritizes ecology and highlights green development should be stuck, he added, adding that achieving common prosperity is one of the most important tasks of socialist modernization; and the government should support ethnic minorities in nurturing competitive industries and prospering their cultures.
He pointed out several aspects the government should work on to bring people benefits, including education, housing, employment, diseases prevention and control system as well as safe production.
Xi also stressed that the Red Army spent the longest time in Guizhou during the Long March, leaving behind precious spiritual treasures. And the Zunyi Conference, held in Zunyi City, is a crucial turning point in the Party's history.
The meeting focused on rectifying errors and established the correct leadership of the new Central Committee, as represented by Mao Zedong, Xi said, making it still matter today.
Original article：here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005631/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom